Kristina Burow
Signal active
Managing Director
Bio
Kristina Burow is the Managing Director of ARCH Venture Partners. She attended The University of Chicago Booth School of Business.
Location
San Francisco, California, United States, North America
Social
Primary Organization
ARCH Venture Partners
Founded
1986
Investment
484
Lead investment
125
Exits
107
Employees
101-250
Industry
Financial Services, Venture Capital, Finance
Jobs history
10
Metsera
Board Member
Invalid date - Current
Mirador Therapeutics
Board of Director
2024 - Current
Magnet Biomedicine
Board of Directors
2023 - Current
Pretzel Therapeutics
Board of Directors
Invalid date - Current
Orbital Therapeutics
Board Member
Invalid date - Current
Board Member
Invalid date - Current
Neumora Therapeutics
Board Member
Invalid date - Current
Remix Therapeutics
Board Observer
Invalid date - Current
Remix Therapeutics
board member
Invalid date - Current
ROME Therapeutics
Board Member
2020 - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Kristina Burow is the Managing Director at ARCH Venture Partners, based in United States, North America. With a background in Financial Services, Kristina Burow has a rich history of leadership and innovation. Kristina Burow studied MA Chemistry @ Columbia University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
N/A
Number of investment
1
Number of exits
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
25
| Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
|---|---|---|---|---|
| Jan 03, 2024 | Remix Therapeutics | Venture Round - Remix Therapeutics | ARCH Venture Partners | 60.0M |
| Mar 21, 2024 | Mirador Therapeutics | Series A - Mirador Therapeutics | ARCH Venture Partners | 400.0M |
| Apr 18, 2024 | Metsera | Series A - Metsera | ARCH Venture Partners | 290.0M |
| Jul 24, 2024 | Autobahn Therapeutics | Series C - Autobahn Therapeutics | ARCH Venture Partners | 100.0M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.